Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

I-branched carbohydrates as emerging effectors of malignant progression.

Dimitroff CJ.

Proc Natl Acad Sci U S A. 2019 Jul 9;116(28):13729-13737. doi: 10.1073/pnas.1900268116. Epub 2019 Jun 18.

PMID:
31213534
2.

Human B Cell Differentiation Is Characterized by Progressive Remodeling of O-Linked Glycans.

Giovannone N, Antonopoulos A, Liang J, Geddes Sweeney J, Kudelka MR, King SL, Lee GS, Cummings RD, Dell A, Barthel SR, Widlund HR, Haslam SM, Dimitroff CJ.

Front Immunol. 2018 Dec 14;9:2857. doi: 10.3389/fimmu.2018.02857. eCollection 2018.

3.

Galectin-Glycan Interactions as Regulators of B Cell Immunity.

Giovannone N, Smith LK, Treanor B, Dimitroff CJ.

Front Immunol. 2018 Dec 4;9:2839. doi: 10.3389/fimmu.2018.02839. eCollection 2018. Review.

4.

Loss of GCNT2/I-branched glycans enhances melanoma growth and survival.

Sweeney JG, Liang J, Antonopoulos A, Giovannone N, Kang S, Mondala TS, Head SR, King SL, Tani Y, Brackett D, Dell A, Murphy GF, Haslam SM, Widlund HR, Dimitroff CJ.

Nat Commun. 2018 Aug 22;9(1):3368. doi: 10.1038/s41467-018-05795-0.

5.

Galectin-9 suppresses B cell receptor signaling and is regulated by I-branching of N-glycans.

Giovannone N, Liang J, Antonopoulos A, Geddes Sweeney J, King SL, Pochebit SM, Bhattacharyya N, Lee GS, Dell A, Widlund HR, Haslam SM, Dimitroff CJ.

Nat Commun. 2018 Aug 17;9(1):3287. doi: 10.1038/s41467-018-05770-9.

6.

Galectin-Binding O-Glycosylations as Regulators of Malignancy.

Dimitroff CJ.

Cancer Res. 2015 Aug 15;75(16):3195-202. doi: 10.1158/0008-5472.CAN-15-0834. Epub 2015 Jul 29. Review.

7.

Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential.

Yazawa EM, Geddes-Sweeney JE, Cedeno-Laurent F, Walley KC, Barthel SR, Opperman MJ, Liang J, Lin JY, Schatton T, Laga AC, Mihm MC, Qureshi AA, Widlund HR, Murphy GF, Dimitroff CJ.

J Invest Dermatol. 2015 Jul;135(7):1849-1862. doi: 10.1038/jid.2015.95. Epub 2015 Mar 10.

8.

Isolation and characterization of chimeric human Fc-expressing proteins using protein a membrane adsorbers and a streamlined workflow.

Burdick MM, Reynolds NM, Martin EW, Hawes JV, Carlson GE, Cuckler CM, Bates MC, Barthel SR, Dimitroff CJ.

J Vis Exp. 2014 Jan 8;(83):e51023. doi: 10.3791/51023.

9.

Human fucosyltransferase 6 enables prostate cancer metastasis to bone.

Li J, Guillebon AD, Hsu JW, Barthel SR, Dimitroff CJ, Lee YF, King MR.

Br J Cancer. 2013 Dec 10;109(12):3014-22. doi: 10.1038/bjc.2013.690. Epub 2013 Oct 31.

10.

Leveraging fluorinated glucosamine action to boost antitumor immunity.

Dimitroff CJ.

Curr Opin Immunol. 2013 Apr;25(2):206-13. doi: 10.1016/j.coi.2012.11.003. Epub 2012 Dec 6. Review.

11.

Definition of molecular determinants of prostate cancer cell bone extravasation.

Barthel SR, Hays DL, Yazawa EM, Opperman M, Walley KC, Nimrichter L, Burdick MM, Gillard BM, Moser MT, Pantel K, Foster BA, Pienta KJ, Dimitroff CJ.

Cancer Res. 2013 Jan 15;73(2):942-52. doi: 10.1158/0008-5472.CAN-12-3264. Epub 2012 Nov 13.

12.

Galectins and their ligands: negative regulators of anti-tumor immunity.

Cedeno-Laurent F, Dimitroff CJ.

Glycoconj J. 2012 Dec;29(8-9):619-25. doi: 10.1007/s10719-012-9379-0. Epub 2012 Apr 29. Review.

13.

Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma.

Cedeno-Laurent F, Watanabe R, Teague JE, Kupper TS, Clark RA, Dimitroff CJ.

Blood. 2012 Apr 12;119(15):3534-8. doi: 10.1182/blood-2011-12-396457. Epub 2012 Mar 1.

14.

Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression.

Cedeno-Laurent F, Opperman M, Barthel SR, Kuchroo VK, Dimitroff CJ.

J Immunol. 2012 Apr 1;188(7):3127-37. doi: 10.4049/jimmunol.1103433. Epub 2012 Feb 17.

15.

Evidence of a novel galectin-9-binding membrane glycoprotein ligand on T helper cells.

Cedeno-Laurent F, Dimitroff CJ.

Clin Immunol. 2012 Apr;143(1):6-7. doi: 10.1016/j.clim.2012.01.010. Epub 2012 Jan 24. No abstract available.

PMID:
22321867
16.

Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity.

Cedeno-Laurent F, Opperman MJ, Barthel SR, Hays D, Schatton T, Zhan Q, He X, Matta KL, Supko JG, Frank MH, Murphy GF, Dimitroff CJ.

J Invest Dermatol. 2012 Feb;132(2):410-20. doi: 10.1038/jid.2011.335. Epub 2011 Dec 8.

17.

Galectin-1 research in T cell immunity: past, present and future.

Cedeno-Laurent F, Dimitroff CJ.

Clin Immunol. 2012 Feb;142(2):107-16. doi: 10.1016/j.clim.2011.09.011. Epub 2011 Oct 6. Review.

18.

Peracetylated 4-fluoro-glucosamine reduces the content and repertoire of N- and O-glycans without direct incorporation.

Barthel SR, Antonopoulos A, Cedeno-Laurent F, Schaffer L, Hernandez G, Patil SA, North SJ, Dell A, Matta KL, Neelamegham S, Haslam SM, Dimitroff CJ.

J Biol Chem. 2011 Jun 17;286(24):21717-31. doi: 10.1074/jbc.M110.194597. Epub 2011 Apr 14.

19.

Development of a nascent galectin-1 chimeric molecule for studying the role of leukocyte galectin-1 ligands and immune disease modulation.

Cedeno-Laurent F, Barthel SR, Opperman MJ, Lee DM, Clark RA, Dimitroff CJ.

J Immunol. 2010 Oct 15;185(8):4659-72. doi: 10.4049/jimmunol.1000715. Epub 2010 Sep 15.

20.

Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking.

Barthel SR, Wiese GK, Cho J, Opperman MJ, Hays DL, Siddiqui J, Pienta KJ, Furie B, Dimitroff CJ.

Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19491-6. doi: 10.1073/pnas.0906074106. Epub 2009 Nov 4.

21.

Analysis of physiologic E-selectin-mediated leukocyte rolling on microvascular endothelium.

Wiese G, Barthel SR, Dimitroff CJ.

J Vis Exp. 2009 Feb 11;(24). pii: 1009. doi: 10.3791/1009.

22.

Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin.

Barthel SR, Gavino JD, Wiese GK, Jaynes JM, Siddiqui J, Dimitroff CJ.

Glycobiology. 2008 Oct;18(10):806-17. doi: 10.1093/glycob/cwn070. Epub 2008 Jul 22.

23.

Skin-homing receptors on effector leukocytes are differentially sensitive to glyco-metabolic antagonism in allergic contact dermatitis.

Gainers ME, Descheny L, Barthel SR, Liu L, Wurbel MA, Dimitroff CJ.

J Immunol. 2007 Dec 15;179(12):8509-18.

24.

Targeting selectins and selectin ligands in inflammation and cancer.

Barthel SR, Gavino JD, Descheny L, Dimitroff CJ.

Expert Opin Ther Targets. 2007 Nov;11(11):1473-91. Review.

25.

Vitamins A and D are potent inhibitors of cutaneous lymphocyte-associated antigen expression.

Yamanaka K, Dimitroff CJ, Fuhlbrigge RC, Kakeda M, Kurokawa I, Mizutani H, Kupper TS.

J Allergy Clin Immunol. 2008 Jan;121(1):148-157.e3. Epub 2007 Oct 1.

26.

The 130-kDa glycoform of CD43 functions as an E-selectin ligand for activated Th1 cells in vitro and in delayed-type hypersensitivity reactions in vivo.

Alcaide P, King SL, Dimitroff CJ, Lim YC, Fuhlbrigge RC, Luscinskas FW.

J Invest Dermatol. 2007 Aug;127(8):1964-72. Epub 2007 Mar 29.

27.
28.

Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells.

Dimitroff CJ, Descheny L, Trujillo N, Kim R, Nguyen V, Huang W, Pienta KJ, Kutok JL, Rubin MA.

Cancer Res. 2005 Jul 1;65(13):5750-60.

29.

Rolling of human bone-metastatic prostate tumor cells on human bone marrow endothelium under shear flow is mediated by E-selectin.

Dimitroff CJ, Lechpammer M, Long-Woodward D, Kutok JL.

Cancer Res. 2004 Aug 1;64(15):5261-9.

30.
31.
32.

Direct real-time observation of E- and P-selectin-mediated rolling on cutaneous lymphocyte-associated antigen immobilized on Western blots.

Fuhlbrigge RC, King SL, Dimitroff CJ, Kupper TS, Sackstein R.

J Immunol. 2002 Jun 1;168(11):5645-51.

33.

differential L-selectin binding activities of human hematopoietic cell L-selectin ligands, HCELL and PSGL-1.

Dimitroff CJ, Lee JY, Schor KS, Sandmaier BM, Sackstein R.

J Biol Chem. 2001 Dec 14;276(50):47623-31. Epub 2001 Oct 8.

34.

CD44 is a major E-selectin ligand on human hematopoietic progenitor cells.

Dimitroff CJ, Lee JY, Rafii S, Fuhlbrigge RC, Sackstein R.

J Cell Biol. 2001 Jun 11;153(6):1277-86.

35.

A distinct glycoform of CD44 is an L-selectin ligand on human hematopoietic cells.

Dimitroff CJ, Lee JY, Fuhlbrigge RC, Sackstein R.

Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13841-6.

36.
37.

Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy.

Dimitroff CJ, Klohs W, Sharma A, Pera P, Driscoll D, Veith J, Steinkampf R, Schroeder M, Klutchko S, Sumlin A, Henderson B, Dougherty TJ, Bernacki RJ.

Invest New Drugs. 1999;17(2):121-35.

PMID:
10638483
38.

Cell surface n-acetylneuraminic acid alpha2,3-galactoside-dependent intercellular adhesion of human colon cancer cells.

Dimitroff CJ, Pera P, Dall'Olio F, Matta KL, Chandrasekaran EV, Lau JT, Bernacki RJ.

Biochem Biophys Res Commun. 1999 Mar 24;256(3):631-6.

PMID:
10080950
39.

Cancer metastasis: a search for therapeutic inhibition.

Dimitroff CJ, Sharma A, Bernacki RJ.

Cancer Invest. 1998;16(4):279-90. Review.

PMID:
9589037
40.

Inhibition of human HT-29 colon carcinoma cell adhesion by a 4-fluoro-glucosamine analogue.

Woynarowska B, Dimitroff CJ, Sharma M, Matta KL, Bernacki RJ.

Glycoconj J. 1996 Aug;13(4):663-74.

PMID:
8872124

Supplemental Content

Loading ...
Support Center